Abstract
Hyperfibrinogenemia and cancer-associated systemic inflammatory response are strongly associated with cancer progression and prognosis. We aimed to develop a novel prognostic score (F-SII score) on the basis of preoperative fibrinogen (F) and systemic immunoinflammatory index (SII), and evaluate its predictive value in patients with resectable gastric cancer (GC). Patients diagnosed with GC between January 2012 and December 2016 were reviewed. The F-SII score was 2 for patients with a high fibrinogen level (≥ 3.37 g/L) and a high SII (≥ 372.8), whereas that for patients with one or neither was 1 or 0, respectively. A high F-SII score was significantly associated with older patient age, a high ASA score, large tumor size, large proportion of perineural invasion, and late TNM stage. Multivariate analysis indicated that the F-SII score, histological grade, and TNM stage were independent factors for overall survival (OS). The Harrell's concordance index (C-index) of a nomogram based on the F-SII score and several clinicopathological manifestations was 0.72, which showed a better predictive ability for OS than the TNM stage alone (0.68). In conclusion, preoperative F-SII may serve as a useful predictive factor for OS and refine outcome prediction for patients with resectable GC combined with traditional clinicopathological analysis.
Similar content being viewed by others
Introduction
Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-associated mortality worldwide1. Despite the significant advances in therapeutic methods, including surgical techniques and adjuvant therapy, the prognosis of GC has not been substantially improved2. Therefore, identifying independent prognostic factors is of utmost importance for optimizing personalized treatment.
Inflammation plays a vital role in the tumor microenvironment and is related to the promotion, progression, invasion, and metastasis of tumors3. Pretreatment serum-based inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR)4, platelet-to-lymphocyte ratio (PLR)5, and lymphocyte-to-monocyte ratio (LMR)6, was used to predict the prognosis of various tumors. Recently, the systemic immune-inflammation index (SII), a newly emerging prognostic score as an integrated expression of neutrophils, lymphocytes, and platelets, is deemed to provide better prognostic information on patients with hepatocellular carcinoma7, pancreatic cancer8, germ-cell tumors9, and gastric cancer10. In addition to inflammatory biomarkers, fibrinogen is a 340-kDa glycoprotein, synthesized as an acute-phase reactant glycoprotein by hepatocytes and has an important role in the coagulation process11. Mounting evidence has reported that hyperfibrinogenemia is related to tumor progression, metastasis, and prognosis in patients with gastric cancer12,13. High SII and elevated fibrinogen independently predict a worse prognosis of GC. However, the evidence is still limited regarding the joint association between both conditions and the prognosis in patients with GC.
Therefore, in this study, we developed a novel prognostic score combining the fibrinogen (F) and systemic immune-inflammation index (F-SII) score, and evaluated the association between the F-SII score and the prognosis in patients with resectable GC. Moreover, a nomogram combining the F-SII score with TNM stage, and histological grade, was established to predict 3- and 5-yr overall survival (OS) for patients with resectable GC.
Results
Patient characteristics
In the present study, a total of 608 patients were included. The median patient age was 61 years (range 25–86 years). The median follow-up period was 56.0 months (interquartile range, 41–71 months). The 1-yr, 3-yr, and 5-yr OS rates for the present study were 85.9%, 58.3%, and 48.0%, respectively. The baseline characteristics of the patients are summarized in Table 1.
Associations of the plasma fibrinogen level, SII, and F-SII score
The univariate analysis showed that the fibrinogen level and SII were associated with OS. Age, ASA score, tumor location, tumor size, histological grade, perineural invasion, and TNM stage also had a significant effect on OS (Table 2). According to our multivariate analysis, the fibrinogen level and SII were independent factors for prognosis (HR, 1.509; 95% CI, 1.181–1.929; P = 0.001; HR, 1.452; 95% CI, 1.128–1.868; P = 0.004, respectively). In addition, well or moderately differentiated tumors and stage I disease were associated with good prognosis in GC (Table 2).
Patients were classified into two independent groups based on the cutoff thresholds of fibrinogen and SII (low < 3.37 g/L or high ≥ 3.37 g/L and low < 372.8 or high ≥ 372.8, respectively) for subsequent analyses. It is showed that decreased plasma fibrinogen and SII were both associated with shorter OS (both P < 0.001) (Fig. 1A,B). To further investigate the effect of the plasma fibrinogen level and SII on patient prognosis, we divided the patients into four groups based on the cutoff thresholds of fibrinogen and SII. Kaplan–Meier analysis indicated obvious differences between the four subgroups (P < 0.001, Fig. 1C). There was no significant difference in subgroups of either plasma fibrinogen ≥ 3.37 g/L or SII ≥ 372.8 (P > 0.05, Fig. 1C). Therefore, we combined the two subgroups. Patients were divided into three F-SII score subgroups based on the following criteria: score 2, both a high fibrinogen level (≥ 3.37 g/L) and a high SII (≥ 372.8); score 1, either a high fibrinogen level or a high SII; and score 0, both a low fibrinogen level (< 3.37 g/L) and a low SII (< 372.8).
The F-SII score independently predicts OS
The univariate analysis showed that the F-SII score had a significant effect on OS (P < 0.001). The results of the multivariate analysis indicated that the F-SII score, histological grade, and TNM stage were independent prognostic factors of OS in GC patients (all P < 0.05) (Table 2). Kaplan–Meier analysis showed that a high F-SII score was associated with short OS (P < 0.05, Fig. 1D). To further analyze the F-SII score's performance in patients with different TNM stages and adjuvant chemotherapy strategies, we conducted a subgroup analysis. When stratified by TNM stage, there was no significant difference in 5-yr OS between the three groups of patients with stage I GC (P = 0.144; Fig. 2A). However, the prognostic value of the F-SII score was maintained for stages II (P = 0.002; Fig. 2B), I–II (P < 0.001; Fig. 2C) and III (P < 0.001; Fig. 2D). The F-SII also stratified OS irrespective of adjuvant chemotherapy administration (P < 0.05; Fig. 3A,B).
Associations of the plasma fibrinogen level, SII, and F-SII score with clinicopathological characteristics
The associations of the plasma fibrinogen level and SII with clinicopathological characteristics are shown in Table 3. Elevated plasma fibrinogen levels and a high SII were associated with older age at surgery (P < 0.001 and P = 0.021), a high ASA score (P = 0.006 and P = 0.015), tumor size ≥ 5 cm (both P < 0.001), and a late TNM stage (both P < 0.001). Moreover, we assessed the association between the F-SII score and clinicopathological factors (Table 3). A high F-SII score was associated with older patient age (P < 0.001), a high ASA score (P = 0.002), large tumor size (P < 0.001), a large proportion of perineural invasion (P = 0.033), and late TNM stage (P < 0.001) (Table 3).
Predictive nomogram for OS
To evaluate the predictive value of the F-SII score, we constructed a nomogram that integrated the independent prognostic factors consisting of TNM stage, histological grade, and F-SII score (Fig. 4A). In this nomogram, each factor was ascribed a weighted point total that indicated a survival prognosis. For internal validation, the calibration curve suggested that the 3- and 5-yr survival rates predicted by the nomogram were consistent with the actual survival rates (Fig. 4B,C). The Harrell's concordance index (C-index) of the nomogram was 0.72, which showed a better predictive ability for OS than the TNM stage (C-index 0.68) and F-SII (C-index 0.62). The areas under the 3-yr and 5-yr ROC curves of the nomogram were 0.797 and 0.80, respectively (Fig. 5A,B). Therefore, combined with the above results, the nomogram is superior to the TNM staging system in predicting the OS of patients with GC.
Discussion
In this study, we confirmed that the preoperative plasma fibrinogen and SII were independent prognostic factors in patients with resectable GC. Moreover, the F-SII score, a newly proposed cumulative score, remained an independent prognostic factor in the multivariate analysis. In addition, its prognostic significance was maintained in the subgroup analysis of patients diagnosed with TNM stages I–II or stage III, as well as patients who did or did not receive adjuvant chemotherapy. We found that a high F-SII score was also associated with older age at surgery, a high ASA score, a large tumor size, the presence of perineural invasion, and a late TNM stage. Then, we developed a prognostic nomogram that included the TNM stage, histological grade, and F-SII score and predicted OS with an accuracy of 0.72. Thus, the F-SII score as an easy and inexpensive indicator might provide important prognostic information to help clinicians estimate the patient outcome by combining with conventional clinicopathological analysis. To the best of our knowledge, this is the first study to determine the clinical value of the F-SII score in patients with resectable GC.
It was reported that plasma fibrinogen is synthesized as an acute-phase reactant glycoprotein by hepatocytes. Several studies have reported the mechanisms of hyperfibrinogenemia in various tumors13,14,15,16. In patients with lung cancer, interleukin-6 produced by tumor cells stimulates the secretion of fibrinogen15. More importantly, fibrinogen, which is synthesized by cancer cells, promotes the proliferation of fibroblast growth factor-216. Finally, plasma fibrinogen promotes tumor cell growth and angiogenesis by interacting with fibroblast growth factor-2 and vascular endothelial growth factor16,17. On the other hand, since Virchow originally made a link between cancer and inflammation in the nineteenth century, a growing body of evidence3,18 has suggested that the levels of inflammatory markers play a vital role in tumor progression and metastasis. Hu et al.7 reported that a high SII was related to liver cirrhosis, a large tumor size, low tumor differentiation, early recurrence, high circulating tumor cell levels, and a poor prognosis in patients with hepatocellular carcinoma. Moreover, Wang et al.10 found that high SII was associated with old age at surgery, poor Borrmann classification, a large tumor size, advanced tumor invasion, lymph node metastasis, distant metastasis, advanced TNM stage, a high CEA level, and poor outcome in patients with gastric cancer. It was reported that a high SII was also connected with sex, the hemoglobin level, and a poor prognosis in patients with small-cell lung cancer19. In the present study, we showed that the plasma fibrinogen level and SII are independent prognostic factors of OS in GC patients. Therefore, we created the F-SII score consisting of the plasma fibrinogen level and SII.
In agreement with previous findings, we demonstrated that both a high fibrinogen level and a high SII (F-SII score 2) are related to advanced tumor stage and a poor prognosis. In contrast, decreased levels of both (F-SII score 0) are related to early tumor stage and a favorable prognosis. Furthermore, a high F-SII score was associated with aggressive tumor biological phenotypes, such as large tumor size, the presence of perineural invasion, and advanced tumor stage. Combined with the above results, the complex interaction between an elevated systemic inflammatory response and tumor progression was partially revealed. Of note, its prognostic significance was still maintained in the subgroup analysis of patients diagnosed with TNM stages I–II or stage III, as well as patients who did or did not receive adjuvant chemotherapy, suggesting that the F-SII score might provide additional prognostic information as a complement to the complete clinicopathological predictive models. As a result, the F-SII score could be an accurate prognostic indicator.
At present, the nomogram fulfills a necessary role in personalisation of oncological treatments by integrating diverse prognostic and determinant variables to generate the probability of a clinical event20. In our study, we developed a nomogram that includes the preoperative TNM stage, histological grade, and F-SII score to improve outcome prediction in GC patients after surgery. We found that the nomogram showed more accurate predictive ability than the TNM stage alone. In addition, the F-SII score can be considered a supplement to physical examinations, such as cross-sectional imaging, endoscopic ultrasonography, and endoscopy, to refine risk stratification in patients with gastric cancer before and after treatment.
The strength of our study is that F-SII score measurements were based on standard laboratory tests of plasma fibrinogen and platelet, neutrophil, and lymphocyte counts, which are routinely used in clinical practice. Nevertheless, our study has certain limitations. First, due to the retrospective nature of the study and the lack of external validation, the prognostic significance of the F-SII score in GC patients remains to be examined prospectively in other populations and larger studies in the future. Second, hematological cell counts may be affected by several factors, though we limited some of the possible confounders. Third, we lacked follow-up information for disease-free survival (DFS), and the application of other survival outcomes may strengthen our findings.
Conclusion
In conclusion, we created a novel and convenient prognostic score named the F-SII score, which was revealed an independent predictor of survival in patients with resectable GC. The F-SII score may be a useful clinical biomarker for identifying patients at high prognostic risk and planning individualized treatment strategies for GC patients.
Methods
Patient characteristics
We collected data from 608 consecutive patients with resectable gastric adenocarcinoma who were treated between January 2012 and December 2016 at the Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University. All patients provided informed consent prior to study participation. This study was approved by the Institutional Review Board of the First Affiliated Hospital of Xi'an Jiaotong University and conducted in compliance with the principles of the Declaration of Helsinki for medical research involving humans. The inclusion criteria of this study were as follows: (1) gastric adenocarcinoma confirmed histopathologically, (2) complete medical records, and (3) underwent radical gastrectomy. The exclusion criteria of this study were as follows: (1) other malignancies, (2) neoadjuvant chemotherapy, (3) metastatic disease, (4) autoimmune or other inflammatory diseases, (5) perioperative mortality, (6) hematological disease, (7) intravenous or arterial embolization within 3 months and (8) continuous anticoagulant therapy. We gathered the following clinical, pathologic, and laboratory data of the patients: age, sex, BMI, American Society of Anesthesiologists (ASA) score, tumor location, tumor size, histological grade, vascular invasion, perineural invasion, lymphatic invasion, TNM stage21, adjuvant chemotherapy, fibrinogen, and SII. In our hospital, 5-fluorouracil-based adjuvant chemotherapy is routinely delivered to patients with advanced GC22.
The SII and F-SII score
Preoperative plasma fibrinogen, lymphocyte, neutrophil, and platelet count levels were examined in samples obtained before breakfast within 7 days prior to surgery23,24. As defined previously, the SII was defined as follows: SII = platelet count × neutrophil count/lymphocyte count7. The optimal cut-off values for plasma fibrinogen (low < 3.37; high ≥ 3.37 g/L) and SII (low < 372.8; high ≥ 372.8) were obtained through ROC curves25. The F-SII score was established based on the combination of different plasma fibrinogen levels and SII values.
Follow‑up
Enrolled patients were prospectively followed-up until June 2019. Patients were routinely followed up every 3 months for the first 2 years after treatment and every 6 months thereafter. Patients evaluations included laboratory tests, a physical examination, multislice computed tomography, and other examinations. OS was defined as the time from the date of surgery to death from any cause or the last follow-up.
Statistical analysis
Statistical analyses were performed using SPSS software (version 25.0; SPSS Inc., Chicago, IL, USA) and R version 3.6.1 software (http://www.r-project.org/). Extension packages, including "survival", "rms", "foreign", and "survivalROC" were also used. Chi-square tests were performed to analyze categorical variables. Kaplan–Meier survival curves were generated, and the log-rank test was performed to compare survival rates. The best cutoff points of plasma fibrinogen and SII were determined using the Youden index and ROC curves. Multivariate analysis using a Cox proportional hazards regression model was used based on variables with a P-value of < 0.05 from the univariate analysis. The nomogram was plotted based on the results of the multivariate analysis. The model's predictive accuracy was estimated by the C-index26 and ROC curve analysis. The calibration plots were applied to verify the performance characteristics of the predictive nomogram. The significance level for all statistical tests was set at 0.05, and all tests were 2-sided.
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-386 (2015).
Kurokawa, Y. et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol. Hepatol. 3, 460–468 (2018).
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
Piciucchi, M. et al. The neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients. Int. J. Mol. Sci. 18, 730 (2017).
Kim, E. Y. et al. The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio: which is better as a prognostic factor in gastric cancer?. Ann. Surg. Oncol. 22, 4363–4370 (2015).
Chan, J. et al. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann. Surg. 265, 539–546 (2017).
Hu, B. et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin. Cancer Res. 20, 6212–6222 (2014).
Aziz, M. et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann. Surg. 270, 139–146 (2019).
Chovanec, M. et al. Systemic immune-inflammation index in germ-cell tumours. Br. J. Cancer 118, 831–838 (2018).
Wang, K. et al. Prognostic value of systemic immune-inflammation index in patients with gastric cancer. Chin. J. Cancer 36, 75 (2017).
Arigami, T. et al. Combined fibrinogen concentration and neutrophil-lymphocyte ratio as a prognostic marker of gastric cancer. Oncol. Lett. 11, 1537–1544 (2016).
Yamashita, H., Kitayama, J. & Nagawa, H. Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn. J. Clin. Oncol. 35, 595–600 (2005).
Yamashita, H., Kitayama, J., Kanno, N., Yatomi, Y. & Nagawa, H. Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 6, 147 (2006).
Yamamoto, M. et al. Usefulness of preoperative plasma fibrinogen versus other prognostic markers for predicting gastric cancer recurrence. World. J. Surg. 40, 1904–1909 (2016).
Yamaguchi, T. et al. Involvement of lnterleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn. J. Clin. Oncol. 28, 740–744 (1998).
Sahni, A., Simpson-Haidaris, P. J., Sahni, S., Vaday, G. & Francis, C. Fibrinogen synthesized by cancer cells augments the proliferative effect of FGF-2. J. Thromb. Haemost. 6, 176–183 (2008).
Sahni, A. & Francis, C. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 96, 3772–3778 (2000).
Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow?. Lancet 357, 539–545 (2001).
Hong, X. et al. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J. Exp. Med. 236, 297–304 (2015).
Kattan, M. Nomograms. Introduction. Semin. Urol. Oncol. 20, 79–81 (2002).
Edge, S. & Compton, C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17, 1471–1474 (2010).
Bang, Y. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315–321 (2012).
Jagadesham, V., Lagarde, S., Immanuel, A. & Griffin, S. Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br. J. Surg. 104, 401–407 (2017).
Wu, Z. et al. Cumulative score based on preoperative fibrinogen and pre-albumin could predict long-term survival for patients with resectable gastric cancer. J. Cancer 10, 6244–6251 (2019).
Lu, J. et al. CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial. Gastric Cancer 22, 536–545 (2019).
Harrell, F., Lee, K. & Mark, D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361–387 (1996).
Acknowledgements
The authors thank American Journal Experts for providing language editing. This study was supported by grants from the National Natural Science Foundation of China (81472245) and the Fundamental Research Funds of the First Affiliated Hospital of Xi'an Jiaotong University (No. 2017QN-01).
Author information
Authors and Affiliations
Contributions
X.M.C. and P.X.W. designed the study; H.J.W., J.H.L., G.L.Q., and J.L collected the data; P.X.W. and L.F. interpreted the results; P.X.W. and X.H.L. prepared the manuscript; All authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wang, PX., Wang, HJ., Liu, JH. et al. A nomogram combining plasma fibrinogen and systemic immune‑inflammation index predicts survival in patients with resectable gastric cancer. Sci Rep 11, 10301 (2021). https://doi.org/10.1038/s41598-021-89648-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-021-89648-9
- Springer Nature Limited
This article is cited by
-
Development and validation of an inflammatory biomarkers model to predict gastric cancer prognosis: a multi-center cohort study in China
BMC Cancer (2024)
-
Pretreatment lymphocyte-monocyte ratio (LMR) as a superior predictor of short-term progression outcomes in patients with gastric cancer receiving second- and later-line apatinib regimens
Journal of Cancer Research and Clinical Oncology (2023)